Blood Bank, Haugesund hospital, Haugesund, Norway.
Medical, NHS Blood and Transplant, Birmingham, UK.
Vox Sang. 2021 Feb;116(2):167-174. doi: 10.1111/vox.12998. Epub 2020 Sep 30.
Whole blood is the original blood preparation but disappeared from the blood bank inventories in the 1980s following the advent of component therapy. In the early 2000s, both military and civilian practice called for changes in the transfusion support for massive haemorrhage. The 'clear fluid' policy was abandoned and replaced by early balanced transfusion of platelets, plasma and red cells. Whole blood is an attractive alternative to multi-component therapy, which offers reduced hemodilution, lower donor exposure and simplified logistics. However, the potential for wider re-introduction of whole blood requires re-evaluation of haemolysins, storage conditions and shelf-life, the need for leucocyte depletion/ pathogen reduction and inventory management for blood providers. This review addresses these questions and calls for research to define the optimal whole blood product and the indications for its use.
全血是最初的血液制剂,但在 20 世纪 80 年代成分治疗出现后,从血库库存中消失。21 世纪初,军事和民用实践都呼吁改变大出血的输血支持。“清亮液体”策略被放弃,代之以早期血小板、血浆和红细胞的平衡输血。全血是多成分治疗的一种有吸引力的替代方法,它可减少血液稀释、降低供者暴露风险并简化物流。然而,要更广泛地重新引入全血,需要重新评估溶血作用、储存条件和保质期、白细胞去除/病原体减少的必要性以及血液提供者的库存管理。本综述讨论了这些问题,并呼吁开展研究以确定最佳的全血产品及其使用指征。